Business Context and Reporting Period
This Form 8-K is filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc., as indicated in the metadata request) on August 12, 2020. The report announces financial results for the quarter ended June 30, 2020. The company is an emerging growth company incorporated in Delaware, with its common stock trading on the Nasdaq Capital Market under the symbol ARPO.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that these results have been announced and directs readers to Exhibit 99.1 (the press release) for the detailed financial data.
Material Changes
The filing does not contain specific data regarding material changes versus the prior comparable period. It solely references the announcement of the Q2 2020 results.
Guidance, Outlook, and Risks
The text does not include specific guidance, outlook, management commentary, or risk factors. It explicitly states that the information furnished in this report and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings, except as expressly set forth.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in Exhibit 99.1 (the press release), as they are not included in the 8-K text.
- Confirm the company name is Aerpio Pharmaceuticals, Inc. (ARPO), noting the discrepancy with the "Whitehawk Therapeutics" label in the request metadata.
- Review the press release for any updates on clinical trial progress or pipeline developments, which are typical for this sector but not detailed in the 8-K summary.
- Check the company's status as an emerging growth company for potential implications on financial reporting standards.